To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
Summary
What This Bill Does
The bill creates short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 and creates reasonable price agreement All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license. It relies on tax rate changes, definition changes, appropriations, and grants. The main policy areas are Healthcare, Science & Space, Healthcare Consumers, and Foreign Policy.
Who Benefits and How
Researchers and scientific institutions affected by the bill could face reduced risk, Patients and health care consumers affected by the bill could face reduced risk, and Foreign businesses and cross-border trade participants affected by the bill could face lower compliance burdens.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.
Key Provisions
- Creates short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023.
- Creates reasonable price agreement All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 and creates reasonable price agreement All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license.
Key Policy Areas
Healthcare, Science & Space, Healthcare Consumers, Foreign Policy
Primary Purpose
The bill creates short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 and creates reasonable price agreement All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license.
Policy Domains
Whole bill
Identified Gains
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
- Foreign businesses and cross-border trade participants affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
Sponsors
Legislative Progress
IntroducedMs. Hoyle of Oregon (for herself, Mr. Doggett, Mr. Cohen, …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology